Effect of Mebo Dressing Versus Standard Care on Managing Donor and Recipient Sites of Split-thickness Skin Graft

• Status: Unknown status
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: All

Summary

40 Egyptian Cases with split-thickness skin graft receiving treatment at Zagazig University Hospitals. Study Duration:6 Months .Description of Agent or Moist Exposed Burn Ointment (MEBO).

Intervention:

Objectives: Primary: to determine the efficacy of MEBO versus standard care in improving the healing speed and re-epithelization process of skin graft donor and recipient sites. Secondary to determine the efficacy of MEBO in decreasing recovery time, rate of infections, rate of complications, total treatment costs and its effect on improving pain alleviation.

Description of Study Design: Arm 1 20 MEBO at sites of donor graft and recipient at time of operation and in dressing Arm 2 20 Standard cream Zagazig University Hospital (Antibiotics & analgesics) Estimated Time to Complete 5 months

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Analgesics; Anti-Bacterial Agents; Antibiotics, Antitubercular

Criteria

Inclusion Criteria:

1. Patients who will be managed using split-thickness skin graft.

2. Donor skin grafts are harvested from a site in the thigh (a minimum of 5 x 5-cm total area).

3. Intention for treatment at Zagazig University.

4. Age between 2 & 60 years.

5. An approved informed consent and authorization permitting release of personal health information must be signed by patient or guardian.

6. Compliance with treatment for 3 weeks.

7. Patients of childbearing age must have a negative pregnancy test.

Exclusion Criteria:

1. Chemical or electrical burns.

2. Patient with concomitant injury of head trauma, inhalation injury, or bone fracture.

3. Pregnant or breast-feeding female.

4. Known or suspected allergies to any of the components of MEBO.

5. Suspicion or presence of active systemic or local cancer or tumor of any kind.

6. Any immune deficiency disorder.

7. Suspected alcohol or drug abuse.

8. Participation in another investigational drug study within 30 days prior to treatment start.

9. If the donor site is less than 5 x 5-cm total area.